Stephen Maxted Ansell, MD, PhD

  • 22862 Citations
  • 81 Scopus h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Stephen Maxted Ansell is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 40 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Specialized Programs of Research Excellence (SPORE) in Human Cancer

Dogan, A. M., Ansell, S. M., Gupta, M. D., Cerhan, J. R., Habermann, T. M., Ratliff, T. L., Link, B. K., Ratliff, T. L., Juweid, M., Ballas, Z., Link, B. K., Ratliff, T., Geyer, S. M., Weiner, G., Lentz, S., Hohl, R. & Smith, B. J.

9/11/026/30/17

Project: Research project

Research Output

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Straus, D. J., Długosz-Danecka, M., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Connors, J. M., Radford, J., Munoz, J., Kim, W. S., Advani, R., Ansell, S. M. & 6 others, Younes, A., Miao, H., Liu, R., Fenton, K., Forero-Torres, A. & Gallamini, A., Mar 5 2020, In : Blood. 135, 10, p. 735-742 8 p.

Research output: Contribution to journalArticle

  • Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma

    Khurana, A., Armand, P. & Ansell, S. M., Apr 15 2020, In : Leukemia and Lymphoma. 61, 5, p. 1063-1074 12 p.

    Research output: Contribution to journalReview article

  • 2 Scopus citations

    Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management

    Ansell, S. M., Jan 1 2020, (Accepted/In press) In : American journal of hematology.

    Research output: Contribution to journalArticle

  • Hodgkin lymphoma and PD-1 blockade

    Merryman, R., Armand, P. & Ansell, S., Jan 1 2020, Hematologic Malignancies. Springer, p. 395-409 15 p. (Hematologic Malignancies).

    Research output: Chapter in Book/Report/Conference proceedingChapter

  • IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

    Sidana, S., Larson, D. P., Greipp, P. T., He, R., McPhail, E. D., Dispenzieri, A., Murray, D. L., Dasari, S., Ansell, S. M., Muchtar, E., Gonsalves, W. I., Kourelis, T. V., Ramirez-Alvarado, M., Kapoor, P., Rajkumar, S. V., Lacy, M. Q., Buadi, F. K., Leung, N., Kyle, R. A., Kumar, S. K. & 2 others, King, R. L. & Gertz, M. A., May 1 2020, In : Leukemia. 34, 5, p. 1373-1382 10 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations